Previous Close | 85.49 |
Open | 86.05 |
Bid | 0.00 x 1400 |
Ask | 100.00 x 900 |
Day's Range | 85.04 - 87.07 |
52 Week Range | 45.38 - 97.24 |
Volume | |
Avg. Volume | 738,968 |
Market Cap | 4.227B |
Beta (5Y Monthly) | 1.08 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.78 |
Earnings Date | May 01, 2024 - May 06, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 102.64 |
Subscribe to Yahoo Finance Plus to view Fair Value for GKOS
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
iDose TR uses Celanese's (CE) VitalDose EVA. It is approved following the completion of two pivotal trials which demonstrates safety and efficacy.
Director Mark Foley has sold 4,560 shares of Glaukos Corp (NYSE:GKOS) on February 23, 2024, according to a recent SEC Filing.